{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T21:29:26Z","timestamp":1775942966302,"version":"3.50.1"},"reference-count":31,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant Agency of the Czech Republic","award":["22-20217K"],"award-info":[{"award-number":["22-20217K"]}]},{"name":"Grant Agency of the Czech Republic","award":["NV19-08-00144"],"award-info":[{"award-number":["NV19-08-00144"]}]},{"name":"Grant Agency of the Czech Republic","award":["NU21-08-00312"],"award-info":[{"award-number":["NU21-08-00312"]}]},{"name":"Grant Agency of the Czech Republic","award":["NU22-05-00374"],"award-info":[{"award-number":["NU22-05-00374"]}]},{"name":"Grant Agency of the Czech Republic","award":["GAUK 1672119"],"award-info":[{"award-number":["GAUK 1672119"]}]},{"name":"Grant Agency of the Czech Republic","award":["SVV260521"],"award-info":[{"award-number":["SVV260521"]}]},{"name":"Grant Agency of the Czech Republic","award":["UNCE\/MED\/016"],"award-info":[{"award-number":["UNCE\/MED\/016"]}]},{"name":"Grant Agency of the Czech Republic","award":["Progres Q26"],"award-info":[{"award-number":["Progres Q26"]}]},{"name":"Grant Agency of the Czech Republic","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]},{"name":"Ministry of Health\u2014AZV","award":["22-20217K"],"award-info":[{"award-number":["22-20217K"]}]},{"name":"Ministry of Health\u2014AZV","award":["NV19-08-00144"],"award-info":[{"award-number":["NV19-08-00144"]}]},{"name":"Ministry of Health\u2014AZV","award":["NU21-08-00312"],"award-info":[{"award-number":["NU21-08-00312"]}]},{"name":"Ministry of Health\u2014AZV","award":["NU22-05-00374"],"award-info":[{"award-number":["NU22-05-00374"]}]},{"name":"Ministry of Health\u2014AZV","award":["GAUK 1672119"],"award-info":[{"award-number":["GAUK 1672119"]}]},{"name":"Ministry of Health\u2014AZV","award":["SVV260521"],"award-info":[{"award-number":["SVV260521"]}]},{"name":"Ministry of Health\u2014AZV","award":["UNCE\/MED\/016"],"award-info":[{"award-number":["UNCE\/MED\/016"]}]},{"name":"Ministry of Health\u2014AZV","award":["Progres Q26"],"award-info":[{"award-number":["Progres Q26"]}]},{"name":"Ministry of Health\u2014AZV","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]},{"name":"Charles University","award":["22-20217K"],"award-info":[{"award-number":["22-20217K"]}]},{"name":"Charles University","award":["NV19-08-00144"],"award-info":[{"award-number":["NV19-08-00144"]}]},{"name":"Charles University","award":["NU21-08-00312"],"award-info":[{"award-number":["NU21-08-00312"]}]},{"name":"Charles University","award":["NU22-05-00374"],"award-info":[{"award-number":["NU22-05-00374"]}]},{"name":"Charles University","award":["GAUK 1672119"],"award-info":[{"award-number":["GAUK 1672119"]}]},{"name":"Charles University","award":["SVV260521"],"award-info":[{"award-number":["SVV260521"]}]},{"name":"Charles University","award":["UNCE\/MED\/016"],"award-info":[{"award-number":["UNCE\/MED\/016"]}]},{"name":"Charles University","award":["Progres Q26"],"award-info":[{"award-number":["Progres Q26"]}]},{"name":"Charles University","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]},{"name":"Charles University Center","award":["22-20217K"],"award-info":[{"award-number":["22-20217K"]}]},{"name":"Charles University Center","award":["NV19-08-00144"],"award-info":[{"award-number":["NV19-08-00144"]}]},{"name":"Charles University Center","award":["NU21-08-00312"],"award-info":[{"award-number":["NU21-08-00312"]}]},{"name":"Charles University Center","award":["NU22-05-00374"],"award-info":[{"award-number":["NU22-05-00374"]}]},{"name":"Charles University Center","award":["GAUK 1672119"],"award-info":[{"award-number":["GAUK 1672119"]}]},{"name":"Charles University Center","award":["SVV260521"],"award-info":[{"award-number":["SVV260521"]}]},{"name":"Charles University Center","award":["UNCE\/MED\/016"],"award-info":[{"award-number":["UNCE\/MED\/016"]}]},{"name":"Charles University Center","award":["Progres Q26"],"award-info":[{"award-number":["Progres Q26"]}]},{"name":"Charles University Center","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]},{"name":"National Institute for Cancer Research","award":["22-20217K"],"award-info":[{"award-number":["22-20217K"]}]},{"name":"National Institute for Cancer Research","award":["NV19-08-00144"],"award-info":[{"award-number":["NV19-08-00144"]}]},{"name":"National Institute for Cancer Research","award":["NU21-08-00312"],"award-info":[{"award-number":["NU21-08-00312"]}]},{"name":"National Institute for Cancer Research","award":["NU22-05-00374"],"award-info":[{"award-number":["NU22-05-00374"]}]},{"name":"National Institute for Cancer Research","award":["GAUK 1672119"],"award-info":[{"award-number":["GAUK 1672119"]}]},{"name":"National Institute for Cancer Research","award":["SVV260521"],"award-info":[{"award-number":["SVV260521"]}]},{"name":"National Institute for Cancer Research","award":["UNCE\/MED\/016"],"award-info":[{"award-number":["UNCE\/MED\/016"]}]},{"name":"National Institute for Cancer Research","award":["Progres Q26"],"award-info":[{"award-number":["Progres Q26"]}]},{"name":"National Institute for Cancer Research","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The transcription factor PU.1 (Purine-rich DNA binding, SPI1) is a key regulator of hematopoiesis, whose level is influenced by transcription through its enhancers and its post-transcriptional degradation via microRNA-155 (miR-155). The degree of transcriptional regulation of the PU.1 gene is influenced by repression via DNA methylation, as well as other epigenetic factors, such as those related to progenitor maturation status, which is modulated by the transcription factor Myeloblastosis oncogene (MYB). In this work, we show that combinatorial treatment of acute myeloid leukemia (AML) cells with DNA methylation inhibitors (5-Azacytidine), MYB inhibitors (Celastrol), and anti-miR-155 (AM155) ideally leads to overproduction of PU.1. We also show that PU.1 reactivation can be compensated by miR-155 and that only a combined approach leads to sustained PU.1 derepression, even at the protein level. The triple effect on increasing PU.1 levels in myeloblasts stimulates the myeloid transcriptional program while inhibiting cell survival and proliferation, leading to partial leukemic differentiation.<\/jats:p>","DOI":"10.3390\/ijms23126729","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T01:48:12Z","timestamp":1655430492000},"page":"6729","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents"],"prefix":"10.3390","volume":"23","author":[{"given":"Petra","family":"Ba\u0161ov\u00e1","sequence":"first","affiliation":[{"name":"BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6479-6592","authenticated-orcid":false,"given":"Helena","family":"Paszekov\u00e1","sequence":"additional","affiliation":[{"name":"BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1019-2195","authenticated-orcid":false,"given":"Lubom\u00edr","family":"Mina\u0159\u00edk","sequence":"additional","affiliation":[{"name":"BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Dluho\u0161ov\u00e1","sequence":"additional","affiliation":[{"name":"BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Burda","sequence":"additional","affiliation":[{"name":"BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7236-6894","authenticated-orcid":false,"given":"Tom\u00e1\u0161","family":"Stopka","sequence":"additional","affiliation":[{"name":"BIOCEV, 1st Medical Faculty, Charles University, 25250 Vestec, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-01-198911","article-title":"Differentiation therapy of leukemia: 3 decades of development","volume":"113","author":"Nowak","year":"2009","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ni973","article-title":"Regulation of macrophage and neutrophil cell fates by the PU.1:C\/EBPalpha ratio and granulocyte colony-stimulating factor","volume":"4","author":"Dahl","year":"2003","journal-title":"Nat. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/ng1361","article-title":"Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1","volume":"36","author":"Rosenbauer","year":"2004","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1073\/pnas.0510616103","article-title":"Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia","volume":"103","author":"Metcalf","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nm.3936","article-title":"Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia","volume":"21","author":"Will","year":"2015","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.biocel.2007.01.026","article-title":"PU.1: A crucial and versatile player in hematopoiesis and leukemia","volume":"40","author":"Kastner","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1756-8722-5-22","article-title":"The significance of low PU.1 expression in patients with acute promyelocytic leukemia","volume":"5","author":"Zhu","year":"2012","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood-2010-08-302976","article-title":"Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells","volume":"117","author":"Leddin","year":"2011","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1101\/gad.1654808","article-title":"PU.1 expression is modulated by the balance of functional sense and antisense RNAs regulated by a shared cis-regulatory element","volume":"22","author":"Ebralidze","year":"2008","journal-title":"Genes Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2011-02-335141","article-title":"Macrophage development from HSCs requires PU.1-coordinated microRNA expression","volume":"118","author":"Ghani","year":"2011","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1084\/jem.20072108","article-title":"Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder","volume":"205","author":"Rao","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/leu.2011.264","article-title":"c-Myb and its target Bmi1 are required for p190BCR\/ABL leukemogenesis in mouse and human cells","volume":"26","author":"Waldron","year":"2012","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1038\/onc.2013.414","article-title":"Aggressive acute myeloid leukemia in PU.1\/p53 double-mutant mice","volume":"33","author":"Basova","year":"2014","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1182\/blood-2010-05-285064","article-title":"MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia","volume":"117","author":"Vargova","year":"2011","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2012.47","article-title":"5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity","volume":"26","author":"Curik","year":"2012","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1515\/hsz-2014-0195","article-title":"Epigenetic control of hematopoiesis: The PU.1 chromatin connection","volume":"395","author":"Rosenbauer","year":"2014","journal-title":"Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood-2015-09-668632","article-title":"Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb\/p300 interaction","volume":"127","author":"Uttarkar","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yu, X., Ruan, X., Zhang, J., and Zhao, Q. (2016). Celastrol Induces Cell Apoptosis and Inhibits the Expression of the AML1-ETO\/C-KIT Oncoprotein in t(8;21) Leukemia. Molecules, 21.","DOI":"10.3390\/molecules21050574"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Coulibaly, A., Haas, A., Steinmann, S., Jakobs, A., Schmidt, T.J., and Klempnauer, K.H. (2018). The natural anti-tumor compound Celastrol targets a Myb-C\/EBPbeta-p300 transcriptional module implicated in myeloid gene expression. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190934"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood-2016-09-740209","article-title":"miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response","volume":"129","author":"Wallace","year":"2017","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/sj.leu.2404645","article-title":"Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts","volume":"21","author":"Durual","year":"2007","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.onc.1200807","article-title":"Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation","volume":"14","author":"Rao","year":"1997","journal-title":"Oncogene"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41467-017-02618-6","article-title":"Peptidomimetic blockade of MYB in acute myeloid leukemia","volume":"9","author":"Ramaswamy","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13159","DOI":"10.1038\/s41598-018-31620-1","article-title":"A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity","volume":"8","author":"Yusenko","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.canlet.2020.01.039","article-title":"Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells","volume":"479","author":"Yusenko","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.18632\/aging.103799","article-title":"In situ self-assembly of Au-antimiR-155 nanocomplexes mediates TLR3-dependent apoptosis in hepatocellular carcinoma cells","volume":"13","author":"Yin","year":"2020","journal-title":"Aging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6617","DOI":"10.1038\/onc.2017.269","article-title":"Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model","volume":"36","author":"Callegari","year":"2017","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12951-019-0490-2","article-title":"Investigation of PLGA nanoparticles in conjunction with nuclear localization sequence for enhanced delivery of antimiR phosphorothioates in cancer cells in vitro","volume":"17","author":"Malik","year":"2019","journal-title":"J. Nanobiotechnology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2014.02.014","article-title":"Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit","volume":"14","author":"Medyouf","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","article-title":"Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia","volume":"30","author":"Ebinger","year":"2016","journal-title":"Cancer Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/12\/6729\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:33:07Z","timestamp":1760139187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/12\/6729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijms23126729"],"URL":"https:\/\/doi.org\/10.3390\/ijms23126729","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]}}}